December 2020
Synthesis of 5-MeO-DMT Succinate
This effort makes the compound available for clinical trials.
Timeline of Psychedelic Featured Events
November 2020
Team Publishes SAR of 17 Psilocybin Analogs
The research team was led by Dr. Adam Klein
September 2020
First Crystal Structure of LSD on 5-HT2A Receptor
The discovery reported by Kim at al. in the journal Cell sheds light on how compounds interact with and activate this canonical receptor.
August 2020
First Clinical Trial Combining LSD and MDMA
MindMed and Liechti Lab join forces for a first-of-its-kind psychedelic clinical trial.
April 2020
MindMed and Liechti Lab Announce LSD “Off-Switch” Technology
This technology may help ease some of the concerns surrounding psychedelic therapy.
February 2020
Study Finds Norpsilocin is More Potent Than Psilocin at 5-HT2A
This is the first scientific evidence that anything but psilocybin or psilocin could potentially contribute to the pharmacology of magic mushrooms.
November 2019
New Magic Mushroom Compounds Identified
Researchers isolate ayahuasca-like compounds known as ß-carbolines from several species of Psilocybe.
January 2019
Study Confirms Psilocin Binding to 5-HT2A Receptor Causes the Psilocybin Psychedelic Experience
Researchers used PET scans, blood psilocin levels, and subjective effects to verify that psilocin binding to 5-HT2A receptors causes the psychedelic experience.
February 7, 2012
fMRI Sees the Effects of Psilocybin on the Human Brain
Researchers find that psilocybin changes blood flow, communication pathways, and activity in the brain, enabling "a state of unconstrained cognition."
December 1, 1998
Vollenweider Finds Psychotic Effects of Psilocybin Happen via 5-HT2 Receptors
Researchers find the psychosis produced from psilocybin in humans is due to activation of serotonin 2A receptors.
1958
Albert Hofmann Isolates Psilocybin and Psilocin
Albert Hofmann isolates psilocybin and psilocin from mushrooms.
November 16, 1938
Albert Hofmann First Synthesizes LSD-25
Albert Hofmann synthesizes LSD-25 for the first time while working at Sandoz Laboratories in Switzerland.